JNJ JOHNSON & JOHNSON
Pharmaceutical Preparations · NYSE · SEC CIK 200406 · Fiscal year ends 01/03
Financial factors as of 2026-09-27 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY7.8%
TTM net income YoY-35.9%
TTM EPS YoY-36.4%
Revenue 3-yr CAGR5.9%
Net income 3-yr CAGR-22.5%
Margins
Gross margin67.6%
Operating margin—
Net margin16.2%
FCF margin20.7%
EBITDA margin—
Returns
ROE20.0%
ROA8.2%
ROIC (approx.)—
Asset turnover0.51x
Leverage & solvency
Liabilities / assets58.7%
Debt / equity0.55x
Current ratio1.02x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.63x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue5.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-28 | FY20242024-12-29 | FY20232023-12-31 | FY20222023-01-01 | FY20212022-01-02 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $94.19B | $88.82B | $85.16B | $79.99B | $78.74B |
| Cost of revenue | $30.26B | $27.47B | $26.55B | $24.60B | $23.40B |
| Gross profit | $63.94B | $61.35B | $58.61B | $55.39B | $55.34B |
| R&D expense | $109.00M | $1.84B | $483.00M | $0 | $0 |
| SG&A expense | $23.68B | $22.87B | $21.51B | $20.25B | $20.12B |
| Interest expense | $971.00M | $755.00M | $772.00M | $276.00M | $183.00M |
| Pretax income | $32.58B | $16.69B | $15.06B | $19.36B | $19.18B |
| Income tax | $5.78B | $2.62B | $1.74B | $2.99B | $1.38B |
| Net income | $26.80B | $14.07B | $35.15B | $17.94B | $20.88B |
| EPS (basic) | 11.13 | 5.84 | 13.88 | 6.83 | 7.93 |
| EPS (diluted) | 11.03 | 5.79 | 13.72 | 6.73 | 7.81 |
| Dividends declared per share | 5.14 | 4.91 | 4.70 | 4.45 | 4.19 |
| Weighted avg. shares (diluted) | 2.43B | 2.43B | 2.56B | 2.66B | 2.67B |
| Balance sheet | |||||
| Cash & equivalents | $19.71B | $24.11B | $21.86B | $14.13B | $14.49B |
| Short-term investments | $393.00M | $417.00M | $1.07B | $9.39B | $17.12B |
| Receivables | $17.18B | $14.84B | $14.87B | $14.04B | $15.28B |
| Inventory | $14.19B | $12.44B | $11.18B | $10.27B | $10.39B |
| Current assets | $55.62B | $55.89B | $53.49B | $55.29B | $60.98B |
| PP&E, net | $23.17B | $20.52B | $19.90B | $17.98B | $18.96B |
| Goodwill | $48.77B | $44.20B | $36.56B | $36.05B | $25.44B |
| Intangibles | $50.40B | $37.62B | $34.17B | $38.49B | $46.39B |
| Total assets | $199.21B | $180.10B | $167.56B | $187.38B | $182.02B |
| Current liabilities | $54.13B | $50.32B | $46.28B | $55.80B | $45.23B |
| Short-term debt | $8.49B | $6.00B | $3.50B | $12.80B | $3.80B |
| Long-term debt | $39.44B | $30.65B | $25.88B | $26.89B | $29.98B |
| Total debt | $47.93B | $36.65B | $29.38B | $39.69B | $33.78B |
| Total liabilities | $117.67B | $108.61B | $98.78B | $110.57B | $108.00B |
| Shareholders' equity | $81.54B | $71.49B | $68.77B | $76.80B | $74.02B |
| Net debt | $28.22B | $12.55B | $7.52B | $25.56B | $19.30B |
| Cash flow statement | |||||
| Operating cash flow | $24.53B | $24.27B | $22.79B | $21.19B | $23.41B |
| Capital expenditure | $4.83B | $4.42B | $4.54B | $4.01B | $3.65B |
| Free cash flow | $19.70B | $19.84B | $18.25B | $17.18B | $19.76B |
| Investing cash flow | -$23.59B | -$18.60B | $878.00M | -$12.37B | -$8.68B |
| Financing cash flow | -$5.54B | -$3.13B | -$15.82B | -$8.87B | -$14.05B |
| Depreciation & amortization | $7.50B | $7.34B | $7.49B | $6.97B | $7.39B |
| Stock-based compensation | $1.35B | $1.18B | $1.16B | $1.14B | $1.14B |
| Share buybacks | $5.95B | $2.43B | $5.05B | $6.04B | $3.46B |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.